Please login to the form below

Not currently logged in

PhRMA names board nominees

Pharmaceutical Research and Manufacturers of America has nominated four industry figures to serve on a new comparative effectiveness board

Pharmaceutical Research and Manufacturers of America (PhRMA) has nominated four industry thought-leaders to serve on the board of the Patient-Centered Outcomes Research Institute (PCORI). The body is a newly created, independent, not-for-profit corporation which will be in charge of steering the controversial comparative effectiveness research agenda mandated under the recently enacted healthcare reform legislation.

The trade group sent a letter to the Government Accountability Office nominating Pfizer chief medical officer Freda Lewis-Hall; Joshua J Ofman, Amgen's vice president of Global Coverage and Reimbursement, Global Government Affairs and vice president of Global Health Economics, Global Development; Michael Rosenblatt, executive vice president and chief medical officer of Merck; and Ellen Strahlman, GlaxoSmithKline's (GSK) senior vice president and chief medical officer.

Three seats on the 21-member PCORI board are reserved for industry representatives. The board will also include the directors of the National Institutes of Health and the Agency for Healthcare Research and Quality, as well as patient advocates, consumer representatives, physicians, nurses, hospital representatives, and representatives for private payers.

The US Comptroller will appoint members to the board for six-year terms and will designate a chair and vice chair. The Institute will also have an internal staff led by an executive director and will receive input from outside experts and consultants.

Lewis-Hall leads Pfizer Medical, the company division "responsible for the safe, effective and appropriate use of every Pfizer medicine and vaccine from its first day of use by a clinical trial volunteer to its final day of patient use anywhere in the world." She has overall accountability for patient safety, regulatory affairs, good clinical practice, pharmacovigilance, medicines quality assurance, external medical affairs and external medical communications.

Ofman is responsible for directing Amgen's activities related to achieving coverage and reimbursement from national payers and oversight of evidence-generation activities to demonstrate the economic value of products.

Rosenblatt was Dean of Tufts University School of Medicine before joining Merck, and earlier in his career was president of Beth Israel Deaconess Medical Centre.

Strahlman is responsible for all global medical, regulatory, safety, medical policy and scientific communications functions for GSK, as well as for patient safety, general medical governance, ethics and integrity, medical information, and investigation involving human subjects.

1st July 2010


COVID-19 Updates and Daily News

Featured jobs


Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...